Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

David Wild

Reporter

Toronto, Canada
David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B drug pricing program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.

Latest From David Wild

Fighting For Diverse Talent in Biopharma

In the United States, where Black inequity has become a focus of diversity efforts, biopharma companies are working hard to recruit and retain individuals from these communities. In fact, the search for such employees and leaders has become so competitive that competition for diverse talent within the industry is now "fierce," as one executive told In Vivo.   

United States Diversity & Inclusion

Accenture's Petra Jantzer On Changing M&A Strategies

In this episode of the In Vivo podcast, David Wild speaks with Petra Jantzer, senior managing director and global life sciences lead at Accenture, about the changing deals landscape. The discussion centers on the shifts in M&A strategies that Jantzer has been seeing among big pharmas and the need for other companies to adapt to a world in which technologies and processes become a key focus of growth.

Business Strategies Commercial

Solving The Data Problem For AI In Drug Discovery

While artificial intelligence has proven its value in drug discovery, for most companies, the power of their AI systems is only as strong as the data those systems are trained on. However, stakeholders – from individual companies to consortiums and service vendors -- are finding creative approaches to overcome the so-called data problem and strengthen their AI models.

Artificial Intelligence Innovation

Sweden: On The Cutting Edge Of Life Sciences

Sweden is a European leader in the life sciences and now has its sights set on becoming a global force in digital and e-health. A rich academic tradition, strong manufacturing infrastructure and health care as a pillar of its unique Mixed Economy make Sweden an attractive home for pharma, biotech and medtech companies and a target for investors.

Sweden Gene Therapy

Meet Frida Lawenius: Director General Of SwedenBIO

With over 300 members involved in all aspects of the life sciences, SwedenBIO's ongoing mission is to make the country’s sector as visible as possible while ensuring each member's interests are being met. The non-profit recently welcomed Frida Lawenius as its Director General and, in a Q&A, she told In Vivo that one of the most pressing challenges facing the sector is recruiting the talent needed to keep up with its growth.

Sweden Leadership

Early Days For The Metaverse In The Life Sciences, But Experimentation Is Happening

Hype around the metaverse has made it a sexy topic, but a recent Accenture report grounds the concept in a sober, yet still exciting, reality. The consulting firm looked at how the metaverse is being applied in the life sciences sector and concluded that while it is early days and the concept remains nebulous, executives would be remiss if they ignored the growing possibilities the metaverse has to offer.

Commercial Artificial Intelligence
See All
UsernamePublicRestriction

Register